1335P1514: S-222611 in combination with anticancer treatments

• Research type

  Research Study

• Full title

  A Phase 1/2, multi-centre, open-label study in patients with HER2 positive breast cancer to assess the tolerability and safety of daily oral administration of S-222611 in combination with various standard anticancer treatments and to examine the potential for pharmacokinetic interactions

• IRAS ID

  149967

• Contact name

  James Spicer

• Contact email

  james.spicer@kcl.ac.uk

• Sponsor organisation

  Shionogi Ltd.

• Eudract number

  2013-003894-87

• REC name

  London - City & East Research Ethics Committee

• REC reference

  14/LO/0641

• Date of REC Opinion

  18 Jul 2014

• REC opinion

  Further Information Favourable Opinion